Session VIII Use in Paediatrics
Chairmani Professor Cefuroxime is a new semi-synthetic cephalosporin with an antibacterial spectrum wider than that of other antibiotics of the same group, due to its increased resistance to enterobacterial 3-, lactamases (O'Callaghan et al. 1976a ). The drug is also active against Hwemophilus influenza?, including ampicillin-resistant strains, and against Neisseria species (O'Callaghan et al. 1976b ). Imperfectly absorbed after oral administration, it must be given parenterally.
Pharmacokinetic studies in adults have been published by Foord (1976) and Goodwin et al. (1977) . Similar studies in infants such as those presented here have not to our knowledge previously been carried out.
Patients and Methods
Twenty-one infants (11 boys and 10 girls) were treated with cefuroxime. Their ages ranged from 3 weeks to 24 months (mean, 6.5 months) and their weights from 2800-9500 g (mean, 6500 g). All were admitted to hospital with symptoms of severe infection, the pathogens responsible for which could be isolated in some cases.
The daily doses of cefuroxime (Table 1) were 60 mg/kg in one case; 45 mg/kg in 18 cases and 30 mg/kg in 2 cases. Fourteen patients were (2) 6-hourly 1-10 daysa Gentamicin (3) (mean = 3.7) 45 (5) a =treatment continued by i.m. injections treated by 8-hourly i.m. injections for periods of 2-13 days (mean, 7.5 days). To 7 patients, the drug was given by slow i.v. injection, at the rate of I injection every 6 h, for periods of 1-10 days (mean, 3.7 days). When necessary, the treatment was continued using the i.m. route. In the 14 patients treated by i.m. injections, no other antibiotic was given. In 3 of the 7 patients treated i.v., cefuroxime was given with i.m. gentamicin in doses of 3 mg/kg/24 h.
Blood samples, collected with capillary tubes and immediately frozen, were taken before treatment and 30 min, 1, 2, 3, 4, 6 and 8 h after i.m. injection. When the drug was given i.v., blood samples were taken 3, 5, 10, 15, 20, 30, 45, 60, 120, 180 and 240 min after injection. Four-hour samples of urine were collected for 12 h after the injection and were also immediately frozen. The serum and urinary concentrations of cefuroxime were measured by a gelose plate microbiological method, using the technique described by Chabbert & Boulingres (1957) . The test organisms were Bacillus ATCC 6633 when the antibiotic was given alone, and Streptococcus fa?calis 761 when it was associated with gentamicin.
RESULTS

Pharmacokinetic Study
The pharmacokinetic study of i.m. cefuroxime was carried out in 11 infants with normal renal function (serum creatinine <10 mg/I). The mean serum level 30 min after an injection of 15 mg/kg was 26.6 jug/ml (s.d. =6.7), but it must be noted that this concentration does not necessarily correspond to the peak serum level. Cefuroxime concentrations of approximately 1.6 ,ug/ml were still measurable at 4 h, but at 6 and 8 h only traces of the drug could be found in the serum (Fig 1) .
The pharmacokinetic study of i.v. cefuroxime was carried out in the 7 infants who received the drug by this route. After a dose of 12.0+2.0 mg/kg injected in 1-3 min, the peak serum level occurred at about 5 min and reached 30.0+8.0 ,tg/ml. Mean cefuroxime concentrations of 5.0 and 1.8 ,ug/ml were still measurable at 180 and 240 min respectively (Fig 2) .
Cefuroxime did not accumulate in the serum during treatment. Assays performed before the HalIf-life S=59.8± 23.6 mmit tively. These figures are not far from the 70 min found by Foord (1976) , but lower than the 120 min found by Goodwin et al. (1977) in adults. The half-life of cefuroxime in infants is between those of cephalothin, cephapirin and cephacetrile which is about 40 min, and those of cephazolin and cephaloridine, which are 120 and 90 min respectively, in adults (O'Callaghan 1975) .
The serum levels obtained after 15 mg/kg are satisfactory, with a peak of about 30 ,ug/ml. After an i.m. or i.v. injection the serum concentrations are still 5 ,tg/ml at 3 h and 1.6-1.9 ,ug/ml at 4 h.
In view of the MICs of most organisms sensitive to cefuroxime (Soussy & Duval 1977) , such serum levels appear to be of value. This applies not only to methicillin sensitive Staphylococcus aureus strains (MICs 1-4 ,g/ml) and to the Streptococci and Pneumococci (MICs 0.032 jug/ml), but also to those Gram negative species that are resistant to cephalothin and sensitive to cefuroxime, i.e. Escherichia coli, Klebsiella pneumonia, Proteus mirabilis, Providentia, Enterobacter and Citrobacter, most of which are inhibited by less than 4,tg/ml. The urinary excretion of cefuroxime in active form and in concentrations of about 190 ,ug/ml makes the drug suitable for the treatment of urinary infections due to sensitive pathogens.
Cefuroxime administered i.m. or i.v. was well tolerated by the treated infants. In particular, no renal toxicity was observed. The incidence of transient eosinophilia was not higher than with other cephalosporins. The dosage we would recommend is 15 mg/kg 8 hourly by i.v. or i.m.
injection.
It would be interesting to discover whether and to what extent cefuroxime crosses the blood brain barrier, as this could be useful for the treatment of ampicillin-resistant Ha?mophilus influenzaw meningitis. Pharmacokinetic studies of the antibiotic in premature babies and in the newborn would also be warranted.
Summary
Twenty-one infants suffering from bronchopulmonary or urinary tract infection were given cefuroxime i.m. or i.v. in daily doses of 30-60 mg/kg. In I I infants blood concentrations of the antibiotic were measured at regular intervals, and urinary concentrations in 3 four-hourly samples.
Following an injection of 15 mg/kg i.m. the mean serum levels were 26.6 ,ug/ml after 30 min and 1.6 ,ug/ml after 4 h. Following 12.0 mg/kg i.v. the mean serum levels were 30 ,ug/ml after 5 min, 5.0 ,ug/ml after 3 h and 1.8 jug/ml after 4 h. No accumulation was detected after repeated injections. Urinary concentrations of 151-181 ,ug/ml after i.m. injection and 180-190 ,ug/ml after i.v. injection were detected. 
Discussion
Cefuroxime, which has interesting bacteriological features among the cephalosporins (Soussy & Duval 1977 ) also has interesting pharmacokinetic features in infants.
After 15 mg/kg i.m. and 12.0±2.0 mg/kg i.v. the sertum half-lives were 64 and 60 min respec-Cefuroxime was effective in 11 out of 13 cases of bronchopulmonary infection and in all 5 cases of Escherichia coli urinary infection. Treatment failed in I case of pleuropneumonia due to cefuroxime resistant Staphylococcus aureus. Apart from moderate and transient eosinophilia in 5 out of 21 patients and reversible shock of obscure origin in I patient no local or systemic adverse effect was observed. Biological tests failed to show any liver or kidney toxicity.
The authors believe that cefuroxime is effective and safe in infants and recommend a dosage of 15 mg/kg eight-hourly by the i.m. or i.v. route.
